Abstract: The present invention relates to the use of a peptide having the amino acid sequence NH2-VCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH-COOH (SEQ ID NO:1) as well as variants, derivatives and fragments of the peptide for the treatment of viral diseases.
Type:
Grant
Filed:
August 16, 2005
Date of Patent:
June 22, 2010
Assignee:
IPF PharmaCeuticals GmbH
Inventors:
Wolf-Georg Forssmann, Frank Kirchhoff, Jan Münch, Ludger Ständker
Abstract: A method of inhibiting the emigration of cells from the intravascular compartment into tissues (or through any membrane limiting any body compartment from another) by confronting the cells with an agonist specific for receptors involved with migration of said cells via a receptor thereby making the cell unresponsive to further activation.
Abstract: The invention relates to peptides with biological activity against infection having the amino acid sequence Z1-LE-X1-IP-X2-X3-X4-P-X5-X6-X7-X8-X9-X10-K-X11-X12-X13-X14-X15-Z2, wherein X1 is a lysine, alanine, or aspartic acid; X2 is a cysteine, methionine or isoleucine; X3 is a serine, cysteine, lysine or glycine; X4 is an isoleucine, alanine, phenylalanine or cysteine; X5 is a proline, D-proline or a substituted L- or D-proline; X6 is a cysteine or glutamic acid; X7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X9 is an amino acid with an aromatic side chain; X10 is a glycine, alanine or asparagine; X11 is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X12 is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X13 is an amino acid with a hydrophobic or an aromatic side chain; X14 is a
Type:
Grant
Filed:
December 19, 2003
Date of Patent:
February 2, 2010
Assignee:
IPF Pharmaceuticals GmbH
Inventors:
Knut Adermann, Frank Kirchhoff, Jan Münch, Axel Schulz
Abstract: The present invention relates to the use of a peptide having the amino acid sequence NH2-VCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH-COOH as well as variants, derivatives and fragments of the peptide for the treatment of viral diseases.
Type:
Application
Filed:
August 16, 2005
Publication date:
December 18, 2008
Applicant:
IPF PharmaCeuticals GmbH
Inventors:
Wolf-Georg Forssmann, Frank Kirchhoff, Jan Munch, Ludger Standker
Abstract: The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
Abstract: The invention relates to tissue inhibitor of metalloproteinase-2 (TIMP-2) as an osteoanabolically active peptide for use as a medicament for treating bone defects, bone diseases and for improving bone regeneration.
Abstract: The invention relates to oligomeric peptides with biological activity against HIV infection having the amino acid sequence (Z1-LE-X1-IP—X2—X3—X4—P—X5—X6—X7—X8—X9—X10—K—X11—X12—X13—X14—X15-Z2)n, wherein n indicates the number of monomeric peptide chains, whereby n is 2, 3 or 4; X1 is a lysine, alanine, or aspartic acid; X2 is a cysteine, methionine or isoleucine; X3 is a serine, cysteine, lysine or glycine; X4 is an isoleucine, alanine, phenylalanine or cysteine; X5 is a proline, D-proline or a substituted L- or D-proline; X6 is a cysteine or glutamic acid; X7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X9 is an amino acid with an aromatic side chain; X10 is a glycine, alanine or asparagine; X11 is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X12 is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahyd
Type:
Application
Filed:
June 17, 2005
Publication date:
May 31, 2007
Applicant:
IPF PHARMACEUTICALS GMBH
Inventors:
Knut Adermann, Frank Kirchhoff, Jan Munch, Axel Schulz, Wolf-Georg Forssmann
Abstract: The invention relates to the polypeptide COM and its derivatives, and methods for its preparation and recovery in a pure or partially purified form from body fluids and tissues, and its use as a medicament.
Type:
Application
Filed:
October 24, 2003
Publication date:
May 11, 2006
Applicant:
IPF Pharmaceuticals GmbH
Inventors:
Wolfgang Meder, Martin Wendland, Harald John, Rudolf Richter, Markus Meyer, Wolf-Georg Forssmann
Abstract: A peptide having the following amino acid sequence: Z1-LEAIPMSIPPEVKFNKPFVF-Z2 (VIRIP) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, polyethylene glycol (PEG) modified, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of VIRIP; wherein Z1 and Z2 are independently a sequence of from 0 to 10 amino acid residues, and if Z1 or Z2=zero amino acid residues, then Z1=H and/or Z2=COOH.
Type:
Grant
Filed:
November 8, 2000
Date of Patent:
May 2, 2006
Assignee:
IPF PharmaCeuticals GmbH
Inventors:
Frank Kirchhoff, Jan Münch, Ludger Ständker, Wolf-Georg Forssmann